| Chi Ha Vu, MD | |
|
1050 W Arkansas Ln Ste 150, Arlington, TX 76013-6308 | |
| (817) 702-1100 | |
| (817) 702-4801 |
| Full Name | Chi Ha Vu |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 26 Years |
| Location | 1050 W Arkansas Ln Ste 150, Arlington, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033171525 | NPI | - | NPPES |
| 8U1312 | Other | TX | BCBS |
| 147990902 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | L0675 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jps Health Network | Fort worth, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Acclaim Physician Group Inc | 4587963582 | 439 |
News Archive
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
New research led by the University of Kent shows that individuals who have consumed moderate amounts of alcohol in social situations are likely to view risky situations with greater caution when considering them as part of a group.
Immune Pharmaceuticals, Inc. announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents.
AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for investigational drug dapagliflozin for the treatment of adults with type 2 diabetes.
Stereological techniques allow biologists to create quantitative, three-dimensional descriptions of biological structures from two-dimensional images of tissue viewed under the microscope. For example, they can accurately estimate the size of a particular subcellular compartment, the total length of a mass of blood vessels, or the number of neurons or synapses in a particular region of the brain.
› Verified 5 days ago
| Entity Name | Acclaim Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780076562 PECOS PAC ID: 4587963582 Enrollment ID: O20160426000707 |
News Archive
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
New research led by the University of Kent shows that individuals who have consumed moderate amounts of alcohol in social situations are likely to view risky situations with greater caution when considering them as part of a group.
Immune Pharmaceuticals, Inc. announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents.
AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for investigational drug dapagliflozin for the treatment of adults with type 2 diabetes.
Stereological techniques allow biologists to create quantitative, three-dimensional descriptions of biological structures from two-dimensional images of tissue viewed under the microscope. For example, they can accurately estimate the size of a particular subcellular compartment, the total length of a mass of blood vessels, or the number of neurons or synapses in a particular region of the brain.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chi Ha Vu, MD Po Box 732973, Dallas, TX 75373-2973 Ph: (817) 702-8450 | Chi Ha Vu, MD 1050 W Arkansas Ln Ste 150, Arlington, TX 76013-6308 Ph: (817) 702-1100 |
News Archive
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
New research led by the University of Kent shows that individuals who have consumed moderate amounts of alcohol in social situations are likely to view risky situations with greater caution when considering them as part of a group.
Immune Pharmaceuticals, Inc. announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents.
AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for investigational drug dapagliflozin for the treatment of adults with type 2 diabetes.
Stereological techniques allow biologists to create quantitative, three-dimensional descriptions of biological structures from two-dimensional images of tissue viewed under the microscope. For example, they can accurately estimate the size of a particular subcellular compartment, the total length of a mass of blood vessels, or the number of neurons or synapses in a particular region of the brain.
› Verified 5 days ago
Dr. Thomas Joseph Miller, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 3600 Matlock Rd Ste 102, Arlington, TX 76015 Phone: 817-467-9096 Fax: 817-472-9338 | |
John Paul Hood, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6201 Matlock Rd, # 139, Arlington, TX 76002 Phone: 817-467-7373 Fax: 817-472-7794 | |
Dennis E Poquiz, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2309 W Green Oaks Blvd, Arlington, TX 76016 Phone: 817-496-4957 Fax: 817-496-3783 | |
Dr. Donna B Baker, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1300 S Fielder Rd, Arlington, TX 76013 Phone: 817-277-2221 | |
Dr. Sherley Aramath, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2415 Matlock Rd, Arlington, TX 76015 Phone: 817-677-2444 | |
Bruce A Henry, M.D.,P.A. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2001 Se Green Oaks Blvd Ste 100, Arlington, TX 76018 Phone: 817-466-7412 Fax: 817-466-7493 |